The Insider Report: Put together for the Subsequent Dip Shopping for Alternative – Daqo New Power (NYSE:DQ), Dianthus Therapeutics (NASDAQ:DNTH)

Market Overview

The turbulence in shares continued with the Nasdaq reeling from the tech wreck. It completed down 2.74%, whereas the Dow Jones Industrial Common and the S&P 500 completed down 1.91% and 1.94%, respectively. The rotation into healthcare continues to speed up, and it is actually the one sector providing plentiful and enticing alternatives. Even so, this selloff seems prolonged and we’re due for a bounce. Crypto, nonetheless, has some points. It is mainly do or die at this level.

Shares I Like

Dianthus Therapeutics (NASDAQ:DNTH) – 95% Return Potential

What’s Occurring

• Dianthus Therapeutics, Inc. (DNTH) is a number one clinical-stage biotechnology firm targeted on creating novel monoclonal antibodies focusing on the complement system for extreme autoimmune and inflammatory illnesses, providing buyers publicity to the quickly rising immunology and precision medication sector with a deal with progressive therapies like DNTH103 for circumstances corresponding to generalized myasthenia gravis and persistent inflammatory demyelinating polyneuropathy.
• The earlier quarter confirmed income of $396k and a lack of $36.77 million.
• This valuation on DNTH is abysmal. Value-to-Gross sales is a whopping 486.21 and E-book Worth is simply 12.75.
• From a technical standpoint, DNTH simply broke out from a wedge sample, which factors to an enormous acceleration in upside momentum.

Why It is Occurring

• Dianthus Therapeutics Inc. is pioneering next-generation complement therapeutics for extreme autoimmune illnesses, with its lead candidate DNTH103—a extremely potent, selective monoclonal antibody—advancing quickly by means of a number of Part 2 trials in underserved neuromuscular circumstances like generalized myasthenia gravis (gMG) and persistent inflammatory demyelinating polyneuropathy (CIDP). This progressive strategy targets the foundation explanation for irritation with subcutaneous dosing each two weeks, addressing vital unmet wants in markets projected to exceed $10 billion by 2030 and positioning Dianthus as a possible chief in precision immunology.
• Breakthrough Part 2 information from the MaGic trial in gMG underscores DNTH103’s best-in-class potential, demonstrating strong efficacy in decreasing signs and bettering high quality of life for sufferers with restricted therapy choices. With enrollment exceeding targets at 65 sufferers and top-line outcomes launched in September 2025, this milestone validates this system’s scientific basis and accelerates the trail to Part 3, fueling a story of transformative influence in uncommon illness care.
• Strategic pipeline acceleration in CIDP and multifocal motor neuropathy builds a neuromuscular franchise with a number of catalysts by means of year-end 2026. The proactive launch of a probably registrational CIDP examine, alongside ongoing trials, diversifies income prospects throughout high-value indications, creating a sturdy growth roadmap that de-risks execution and faucets into rising demand for complement-targeted therapies in immunology.
• Robust institutional momentum displays rising confidence in Dianthus’s trajectory, with outstanding biotech buyers like Baker Bros. Advisors and Braidwell LP including or sustaining positions in Q3 2025 13F filings. This inflow of refined capital, alongside a $150 million public providing in September 2025, bolsters the corporate’s monetary runway into 2027, enabling aggressive development with out dilution pressures and signaling undervalued potential within the biotech sector.
• Analyst Rankings:

My Motion Plan (95% Return Potential)

• I’m bullish on DNTH above $35.00-$36.00. My upside goal is $80.00-$82.00.

Daqo New Power (NYSE:DQ) – 78% Return Potential

What’s Occurring

• Daqo New Power Corp. (DQ) is a number one producer of high-purity polysilicon, a vital uncooked materials for photo voltaic photovoltaic merchandise, providing buyers publicity to the quickly rising renewable power and solar energy sector with a deal with superior manufacturing processes and international sustainability initiatives.
• The final quarterly report confirmed income of $244.60 million however no earnings.
• Valuation is fairly sturdy in DQ. Value-to-Gross sales is round 3.60 however E-book Worth is 64.93, suggesting it is on sale.
• From a technical perspective, DQ simply broke out from an ascending triangle formation. This indicators a continuation of the uptrend is in impact.

Why It is Occurring

• Daqo New Power Corp. is driving the worldwide solar energy surge as a number one polysilicon producer, with its high-purity supplies fueling the photovoltaic provide chain amid accelerating renewable power adoption worldwide. As governments and companies decide to net-zero targets, Daqo’s established manufacturing capability positions it to learn from the explosive progress in photo voltaic installations, projected to exceed 1 TW yearly by 2030, making a resilient narrative of important infrastructure within the clear power transition.
• Operational resilience and price efficiencies spotlight Daqo’s aggressive edge in a risky market. Regardless of business headwinds, the corporate’s deal with low-cost manufacturing in China has sustained profitability, with Q2 2025 outcomes showcasing disciplined execution and a path to stabilizing margins as polysilicon costs get better, reinforcing its story as a battle-tested participant able to capitalize on the long-term upcycle in photo voltaic demand.
• Strategic enlargement into wafers diversifies Daqo’s income past polysilicon, tapping into higher-value segments of the PV ecosystem. The Polysilicon and Wafer segments allow vertical integration, decreasing publicity to uncooked materials value swings whereas capturing extra of the worth chain, positioning the corporate for enhanced progress as module producers search dependable, end-to-end suppliers in a fragmented market.
• Geopolitical neutrality and international provide function strengthen Daqo’s worldwide attraction. By serving photovoltaic producers throughout Asia, Europe, and North America, the corporate navigates commerce tensions by means of diversified buyer base and know-how management, constructing a story of indispensable reliability within the quest for power independence and sustainable energy options.
• Analyst Rankings:

My Motion Plan (78% Return Potential)

• I’m bullish on DQ above $27.00-$28.00. My upside goal is $50.00-$52.00.

Arcus Biosciences (NYSE:RCUS) – 45% Return Potential

What’s Occurring

• Arcus Biosciences, Inc. (RCUS) is a number one clinical-stage biopharmaceutical firm creating differentiated molecules and mixture therapies for most cancers and inflammatory illnesses, providing buyers publicity to the quickly rising oncology and immunology sector with a deal with progressive remedies like domvanalimab and casdatifan for lung most cancers and renal cell carcinoma.
• The corporate shared income of $26 million of their newest quarter, however nonetheless had a lack of $135 million.
• Valuation in RCUS is sky-high. Value-to-Gross sales is at 8.38 and E-book Worth is simply 3.52.
• From a charting perspective, RCUS is consolidating its current features inside a rectangle sample, which factors to extra upside.

Why It is Occurring

• Arcus Biosciences Inc. is advancing its progressive TIGIT pathway inhibitors to rework most cancers immunotherapy, with domvanalimab + zimberelimab demonstrating superior efficacy in Part 3 NSCLC trials—decreasing development danger by 37% versus pembrolizumab alone. This breakthrough positions Arcus as a frontrunner in a $50 billion+ immuno-oncology market, addressing resistance challenges in lung most cancers and unlocking potential for broader stable tumor functions amid surging demand for next-gen therapies.
• Casdatifan program’s late-stage momentum fuels Arcus’s oncology pipeline progress. With Part 3 initiation in clear cell renal cell carcinoma (ccRCC) backed by compelling Part 1b information exhibiting 80% response charges together with cabozantinib, casdatifan presents best-in-class HIF-2α inhibition—tapping right into a $10 billion RCC market and making a narrative of precision medication management for genetically pushed cancers.
• Strategic collaborations with AstraZeneca and Gilead amplify Arcus’s international attain and validation. The expanded AstraZeneca partnership for Part 3 trials in NSCLC and RCC, alongside Gilead’s $1.5 billion TIGIT possibility train, present non-dilutive funding and co-development firepower—reinforcing Arcus’s story as a biotech innovator with de-risked belongings and accelerated paths to commercialization in high-unmet-need indications.
• Sturdy monetary place post-offering helps aggressive pipeline execution. The November 2025 completion of a $269.7 million inventory providing extends Arcus’s money runway into 2028, funding a number of Part 3 readouts and new indications with out instant dilution pressures—positioning the corporate to navigate biotech volatility whereas capitalizing on medical catalysts in 2026.
• Analyst Rankings:

My Motion Plan (45% Return Potential)

• I’m bullish on RCUS above $17.00-$17.50. My upside goal is $32.00-$33.00.

Market-Transferring Catalysts for the Week Forward

Vacation Buying and selling Begins

We’re getting into one of the vital bullish durations of the yr from a seasonal standpoint. The back-half of November is traditionally one of many strongest occasions of the yr, and after the turbulence of current weeks, bulls have this to sit up for.

However this is not all to sit up for this week, because the Thanksgiving vacation comes round on Thursday right here in the USA. It is a day to provide thanks for all that we now have, however in actuality, we must be training gratitude way more usually than simply for a day.

Over time, I’ve discovered it extra vital to take these relaxation days once they come. With 24 hour buying and selling coming sooner or later, we’ll have to seek out methods to unplug from the markets. That reset is essential for conserving a transparent and degree head.

A Greenback Rebound in 2026?

A rebound within the U.S. greenback throughout 2026 may show bullish for home shares by easing a number of headwinds that weighed on markets in 2025. A stronger greenback usually indicators bettering U.S. progress expectations and enticing interest-rate differentials, encouraging overseas capital inflows into U.S. belongings and supporting larger fairness valuations.

It additionally permits the Federal Reserve to maintain chopping charges with out fears of foreign money collapse or imported inflation. For U.S.-centric corporations (which dominate the S&P 500), a firmer greenback reduces the interpretation drag on overseas earnings and calms issues about aggressive devaluation overseas.

And maybe most significantly, a orderly greenback restoration usually coincides with “U.S. exceptionalism” regimes by which home shares outperform international friends, attracting much more allocation towards U.S. equities and making a self-reinforcing bullish cycle.

Sector & Business Power

That is the most important shift I’ve seen at a sector degree in months. Going again to the beginning of Q3, we now see healthcare (XLV) because the undisputed chief within the S&P, whereas know-how (XLK) has dropped down to 3rd place.

Utilities (XLU) are holding up in second place, so we now have a state of affairs the place two defensive sectors in healthcare and utilities are outperforming. This isn’t a robust sign for bulls within the near-term.

Bulls can relaxation on the truth that staples (XLP) are nonetheless close to the underside of the pack, and it would not take a lot of a rebound in tech to convey it again into first place. However for now, we’re higher off exercising endurance.

Editor’s Notice: Healthcare’s momentum retains accelerating.

Thankfully, this solely seems to be a short lived bump within the street. The pattern on this ratio under may be very clearly to the upside, as it has been making higher-highs and higher-lows. We even look to be within the technique of forming a higher-low right here.

However let’s not lose sight of the truth that the ratio broke out from the wedge formation again in the summertime. It is a momentum sample, and so as soon as this pullback within the ratio is over, I will be searching for tech to reemerge as the large mover in markets.

Is the U.S. the Place to Be Once more? (Sector ETF: SPY/VT) 

One of many massive themes of 2025 was worldwide shares outperforming U.S. shares by a large margin for the primary time in a few years. Nevertheless, with the prospect of an enormous rebound within the Greenback, may we see a reversion again to the pattern that is dominated the previous a number of years?

I am trying on the ratio right here between the S&P 500 (SPY) and a complete world inventory fund (VT). The ratio right here is in a broader uptrend, however over the previous couple of years, we have seen it consolidate right into a symmetrical triangle formation.

I am awaiting a break above the higher trendline of the sample, as that might result in an enormous breakout from the triangle, and level to a continuation within the uptrend. This might result in a serious inflow of capital again into the U.S. market.

Stress in Junk (Sector ETF: HYG/IEI) 

I wish to dive a bit deeper into some key credit score ratios, as a result of there’s some rising stress that must be resolved ahead of later if this rally in shares goes to proceed. Sure, bonds and shares are related to 1 one other in such a fashion.

I am trying on the ratio between junk bonds (HYG) and 3-7 Yr Treasuries (IEI). The important thing right here is to see HYG outperform IEI. In different phrases, junk bonds must outperform Treasuries. This indicators confidence from capital markets and powerful liquidity circumstances.

The ratio is coming again down after testing resistance of a saucer formation. Larger image, I believe we are going to see an enormous breakout subsequent yr, however near-term, seeing this ratio drop does elevate a cautionary sign. It is most likely ready for a sign from the Fed.

My Take:

Junk bonds have a status of buying and selling much like shares with respect to volatility. That stated, they’re nonetheless larger up on the capital ladder in comparison with shares. Bulls must see this ratio rebound if shares are going to see a vacation rally.

The Fed watches ratios like these. In concept, fee cuts would assist to ease the issue in bond markets and provides junk bonds a lift. It seems like we obtained some favorable rhetoric from Fed officers previously week too.

Cryptocurrency 

The downward drift in crypto continued final week, and we’re nonetheless searching for extra concrete indicators of a bounce. To be clear – it seems like we’re nearer to the tip of this decline than we’re the start, however we nonetheless should be alert for extensive value swings.

Since Ethereum misplaced the important thing 3200-3300 degree of help, it now turns into resistance. There are some critical technical headwinds now that Ethereum is under this zone. The following degree it could take a look at is within the 2600-2800 zone.

I do not suppose this modifications a lot for the larger image in 2026. In actual fact, I’m searching for Ethereum to be again at new all-time highs in 2026, and even testing the 6,000 zone. Let’s examine if it could actually get again into the descending channel quickly.

Authorized Disclosures:

This communication is supplied for data functions solely. 

This communication has been ready primarily based upon data, together with market costs, information and different data, from sources believed to be dependable, however Benzinga doesn’t warrant its completeness or accuracy besides with respect to any disclosures relative to Benzinga and/or its associates and an analyst’s involvement with any firm (or safety, different monetary product or different asset class) that could be the topic of this communication. Any opinions and estimates represent our judgment as of the date of this materials and are topic to alter with out discover. Previous efficiency will not be indicative of future outcomes. This communication will not be supposed as a suggestion or solicitation for the acquisition or sale of any monetary instrument. Benzinga doesn’t present individually tailor-made funding recommendation. Any opinions and proposals herein don’t bear in mind particular person consumer circumstances, goals, or wants and usually are not supposed as suggestions of explicit securities, monetary devices or methods to explicit shoppers. You will need to make your individual unbiased selections concerning any securities, monetary devices or methods talked about or associated to the knowledge herein. Periodic updates could also be supplied on corporations, issuers or industries primarily based on particular developments or bulletins, market circumstances or some other publicly out there data. Nevertheless, Benzinga could also be restricted from updating data contained on this communication for regulatory or different causes. Shoppers ought to contact analysts and execute transactions by means of a Benzinga subsidiary or affiliate of their residence jurisdiction except governing regulation permits in any other case.

This communication will not be redistributed or retransmitted, in entire or partly, or in any kind or method, with out the categorical written consent of Benzinga. Any unauthorized use or disclosure is prohibited. Receipt and evaluate of this data constitutes your settlement to not redistribute or retransmit the contents and data contained on this communication with out first acquiring categorical permission from a licensed officer of Benzinga. Copyright 2022 Benzinga. All rights reserved.